Literature DB >> 8063283

The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.

B G Skov1, A F Lauritzen, F Hirsch, H W Nielsen.   

Abstract

In a randomized design we examined the interobserver variation in the histopathological diagnosis of adenocarcinoma of the lung and malignant mesothelioma. In three rounds, three pathologists assessed slides from 42 tumours originally diagnosed as adenocarcinomas, malignant mesotheliomas or benign lesions in the pleura. In the first round the assessments were made on haematoxylin and eosin (H & E) stained sections; in the second, on H & E sections plus sections stained with histochemical mucin stains; and in the final round, the diagnoses were made on H & E sections and sections stained with a panel of antibodies against various antigens (cytokeratin, EMA, CEA, Ber-EP4, B72.3, Leu-M1, vimentin and S-100 protein) said to be of value in the differential diagnosis. The overall interobserver agreements for the three rounds were 0.659, 0.802 and 0.817; the kappa values were 0.461, 0.681 and 0.690. It is concluded that differentiation between adenocarcinoma of the lung and malignant mesothelioma should be made on sections stained with H & E and mucin and/or immunohistochemical staining reactions, including antibodies against B72.3, Ber-EP4 and CEA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8063283     DOI: 10.1111/j.1365-2559.1994.tb00575.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

1.  HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.

Authors:  A D Kennedy; G King; K M Kerr
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

Review 2.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

3.  Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.

Authors:  F Roberts; A E McCall; R A Burnett
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

4.  Inter-observer variation between pathologists in diffuse parenchymal lung disease.

Authors:  A G Nicholson; B J Addis; H Bharucha; C A Clelland; B Corrin; A R Gibbs; P S Hasleton; K M Kerr; N B N Ibrahim; S Stewart; W A H Wallace; A U Wells
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

5.  Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.

Authors:  Derya Gümürdülü; E Handan Zeren; Philip T Cagle; Fazilet Kayasel uk; Nazan Alparslan; Ali Kocabas; Ilhan Tuncer
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

6.  Malignant mesothelioma of the pleura: interobserver variability.

Authors:  A Andrion; C Magnani; P G Betta; A Donna; F Mollo; M Scelsi; P Bernardi; M Botta; B Terracini
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.